VivoSim Labs (NASDAQ: VIVS) has received a prestigious "Poster of Distinction" award at the Digestive Disease Week Conference for its NAMkind™ intestinal platform. The platform represents a breakthrough in non-animal testing methods (NAM) for drug development, particularly for inflammatory bowel disease (IBD) treatments. The system uses primary human cells from both healthy donors and IBD patients to create models that accurately reflect intestinal biology and disease characteristics. This development aligns with the FDA's recent announcement to phase out animal testing requirements, positioning VivoSim to disrupt the >$10B animal testing market. The company's technology combines AI-based computational modeling with human organ model-based lab testing, aiming to provide more predictive and ethically sound solutions for pharmaceutical testing, particularly in areas like chemotherapy-related intestinal side effects.
VivoSim Labs (NASDAQ: VIVS) ha ricevuto il prestigioso premio "Poster of Distinction" durante la Digestive Disease Week Conference per la sua piattaforma intestinale NAMkind™. Questa piattaforma rappresenta una svolta nelle metodologie di test non animali (NAM) per lo sviluppo di farmaci, in particolare per i trattamenti delle malattie infiammatorie intestinali (IBD). Il sistema utilizza cellule umane primarie provenienti sia da donatori sani che da pazienti con IBD per creare modelli che riflettono con precisione la biologia intestinale e le caratteristiche della malattia. Questo sviluppo è in linea con la recente decisione della FDA di eliminare gradualmente i requisiti di test sugli animali, posizionando VivoSim come un attore destinato a rivoluzionare un mercato dei test sugli animali che supera i 10 miliardi di dollari. La tecnologia dell'azienda combina la modellazione computazionale basata sull'intelligenza artificiale con test di laboratorio basati su modelli di organi umani, con l'obiettivo di offrire soluzioni più predittive ed eticamente responsabili per i test farmaceutici, specialmente in ambiti come gli effetti collaterali intestinali legati alla chemioterapia.
VivoSim Labs (NASDAQ: VIVS) ha recibido el prestigioso premio "Poster of Distinction" en la Conferencia Digestive Disease Week por su plataforma intestinal NAMkind™. Esta plataforma representa un avance en los métodos de prueba sin animales (NAM) para el desarrollo de medicamentos, especialmente para tratamientos de la enfermedad inflamatoria intestinal (IBD). El sistema utiliza células humanas primarias tanto de donantes sanos como de pacientes con IBD para crear modelos que reflejan con precisión la biología intestinal y las características de la enfermedad. Este desarrollo está alineado con el reciente anuncio de la FDA para eliminar progresivamente los requisitos de pruebas en animales, posicionando a VivoSim para revolucionar un mercado de pruebas en animales que supera los 10 mil millones de dólares. La tecnología de la compañía combina modelado computacional basado en inteligencia artificial con pruebas de laboratorio basadas en modelos de órganos humanos, con el objetivo de ofrecer soluciones más predictivas y éticamente responsables para las pruebas farmacéuticas, especialmente en áreas como los efectos secundarios intestinales relacionados con la quimioterapia.
VivoSim Labs(NASDAQ: VIVS)는 NAMkind™ 장 플랫폼으로 Digestive Disease Week 컨퍼런스에서 권위 있는 "Poster of Distinction" 상을 받았습니다. 이 플랫폼은 특히 염증성 장 질환(IBD) 치료제 개발을 위한 비동물 시험 방법(NAM) 분야에서 획기적인 진전을 보여줍니다. 이 시스템은 건강한 기증자와 IBD 환자의 1차 인간 세포를 사용하여 장 생물학과 질병 특성을 정확히 반영하는 모델을 만듭니다. 이러한 개발은 FDA가 동물 실험 요구사항을 단계적으로 폐지하기로 한 최근 발표와 일치하며, VivoSim은 100억 달러 이상의 동물 실험 시장을 혁신할 위치에 있습니다. 회사의 기술은 인공지능 기반 컴퓨터 모델링과 인간 장기 모델 기반 실험실 테스트를 결합하여, 특히 화학요법 관련 장 부작용 같은 분야에서 제약 테스트를 위한 보다 예측 가능하고 윤리적인 솔루션을 제공하는 것을 목표로 합니다.
VivoSim Labs (NASDAQ : VIVS) a reçu le prestigieux prix "Poster of Distinction" lors de la conférence Digestive Disease Week pour sa plateforme intestinale NAMkind™. Cette plateforme représente une avancée majeure dans les méthodes de test sans animaux (NAM) pour le développement de médicaments, notamment pour les traitements des maladies inflammatoires de l'intestin (MII). Le système utilise des cellules humaines primaires provenant à la fois de donneurs sains et de patients atteints de MII afin de créer des modèles reflétant fidèlement la biologie intestinale et les caractéristiques de la maladie. Ce développement s'inscrit dans la dernière annonce de la FDA visant à supprimer progressivement les exigences de tests sur les animaux, positionnant VivoSim pour bouleverser un marché des tests sur animaux de plus de 10 milliards de dollars. La technologie de l'entreprise combine la modélisation informatique basée sur l'IA avec des tests en laboratoire basés sur des modèles d'organes humains, visant à fournir des solutions plus prédictives et éthiques pour les tests pharmaceutiques, notamment dans des domaines comme les effets secondaires intestinaux liés à la chimiothérapie.
VivoSim Labs (NASDAQ: VIVS) hat auf der Digestive Disease Week Konferenz den angesehenen "Poster of Distinction"-Preis für seine NAMkind™ Darmplattform erhalten. Die Plattform stellt einen Durchbruch bei nicht-tierischen Testmethoden (NAM) für die Arzneimittelentwicklung dar, insbesondere für die Behandlung von entzündlichen Darmerkrankungen (IBD). Das System verwendet primäre menschliche Zellen von gesunden Spendern sowie von IBD-Patienten, um Modelle zu schaffen, die die Darmbiologie und Krankheitsmerkmale präzise widerspiegeln. Diese Entwicklung steht im Einklang mit der aktuellen Ankündigung der FDA, die Anforderungen an Tierversuche schrittweise abzuschaffen, und positioniert VivoSim, um den mehr als 10 Milliarden Dollar schweren Tierversuchsmarkt zu revolutionieren. Die Technologie des Unternehmens kombiniert KI-basierte computergestützte Modellierung mit Laborversuchen auf Basis menschlicher Organmodelle, mit dem Ziel, besonders in Bereichen wie den durch Chemotherapie bedingten Darmnebenwirkungen, vorhersagbarere und ethisch vertretbare Lösungen für pharmazeutische Tests anzubieten.
Positive
Recognition with blue ribbon award validates technology effectiveness
Platform aligns with FDA's new direction to phase out animal testing
Potential to disrupt $10B+ animal testing market
Models demonstrate responsiveness to clinical therapeutics
Technology combines AI with human organ models for better predictability
Negative
None.
SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon “Poster of Distinction” award at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025). The work describes developing a robust, multicellular in vitro model that closely mirrors human intestinal biology, paving the way for safer and more effective therapies for inflammatory bowel disease (IBD).
The Company’s award-winning research showcased a physiologically relevant system built from primary human cells derived from both healthy donors and patients with Ulcerative Colitis or Crohn’s Disease. These models exhibit gene expression and phenotypic characteristics that strongly align with native human intestinal tissue, including hallmark features of IBD such as epithelial barrier dysfunction and fibrosis. Importantly, the Company’s platform demonstrated responsiveness to clinically used therapeutics, confirming its potential for identifying compounds that promote mucosal healing and prevent stricture formation – two critical goals in IBD treatment. Moreover, the system is showing early promise in distinguishing between older treatments and emerging therapies that may offer improved safety and efficacy,
VivoSim offers liver and intestinal toxicology insights using its premier new approach methodologies (NAM) models, following the announcement of FDA to phase out animal testing requirements in favor of these non-animal NAM methods. The FDA’s push to phase out animal models, announced on April 10, is expected to provide a powerful accelerant to VivoSim’s market adoption, disrupting a >$10B animal testing market with models that are more predictive and ethically sound.
VivoSim’s NAMkind™ intestine model is a physical wet lab model of intestine made using cells from human donors. VivoSim is also developing what it believes will be industry-best in silico predictions of intestinal tox. Artificial intelligence (AI) models in VivoSim’s NAMkind™ services suite will be trained on extensive set of proprietary, real-world data from NAM models made from human donor cells, giving much richer and more extensive information than is possible with data from human clinical trials.
VivoSim’s NAMkind™ intestine models can also deliver readouts on endpoints that are today not available to industry scientists selecting from many candidate drug molecules. As a result of the lack of such tools, a cancer patient might suffer nausea, vomiting, or intestinal problems, or a patient’s needed chemotherapy dose might be lower than it could be due to such conditions. VivoSim aims to provide transformative solutions for these challenges.
The FDA has laid out ambitious goals to phase out animal testing requirements as much as possible. VivoSim is launching to fill in the much-needed gap in commercially available solutions. The technology exists to achieve FDA Commissioner Marty A. Makary’s vision, which he expressed in March 2025 with the rollout of FDA’s push to move away from animal testing and towards NAM models. “By leveraging AI-based computational modeling, human organ model-based lab testing, and real-world human data, we can get safer treatments to patients faster and more reliably, while also reducing R&D costs and drug prices,” Makary noted. By leveraging AI-based computational modeling, human organ model-based lab testing, VivoSim is delivering on the promise of this technology, and will use its proprietary methods and cutting-edge capabilities for NAMkind™ models that displace use of animals and provide superior outcomes for its pharmaceutical customers, ultimately delivering better solutions for patients.
Forward Looking Statements Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding the Company’s expectations that its model paves the way for safer and more effective therapies for IBD and that the models are more predictive and ethically sound, the Company’s expectations regarding its market adoption, the Company’s belief that it is developing an industry-best in silico predictions of liver tox, the Company’s expectations about its AI models in the Company’s NAMkind™ services suite, the Company’s plan to provide transformative solutions for certain challenges, including that a cancer patient might suffer nausea, vomiting, or intestinal problems, or a patient’s needed chemotherapy dose might be lower than it could be and that the Company will deliver on its end goal of providing better solutions for patients. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on May 31, 2024, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on February 19, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.
What is VivoSim's (VIVS) NAMkind™ intestine platform and how does it work?
NAMkind™ is a physical wet lab model of intestine made using cells from human donors, designed to predict intestinal efficacy. It uses primary human cells from both healthy donors and IBD patients to create models that mirror human intestinal biology and respond to clinical therapeutics.
How does the FDA's decision to phase out animal testing affect VivoSim (VIVS)?
The FDA's decision positions VivoSim favorably to disrupt the $10B+ animal testing market by providing non-animal testing alternatives that are more predictive and ethically sound.
What recognition did VivoSim (VIVS) receive at the Digestive Disease Week Conference 2025?
VivoSim received a blue ribbon 'Poster of Distinction' award for its NAMkind™ intestinal platform at the conference held in San Diego from May 2-6, 2025.
How does VivoSim's (VIVS) technology aim to improve drug development?
The technology combines AI-based computational modeling with human organ model-based testing to provide more accurate predictions of drug effects, potentially leading to safer treatments and reduced R&D costs.
What specific conditions can VivoSim's (VIVS) NAMkind™ platform help study?
The platform specifically helps study inflammatory bowel disease (IBD), including Ulcerative Colitis and Crohn's Disease, and can evaluate chemotherapy-related intestinal side effects.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
